TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype
- 12 February 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 113 (2), 217-230
- https://doi.org/10.1007/s10549-008-9924-5
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAILNature Medicine, 2007
- Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitroBreast Cancer Research and Treatment, 2007
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006
- Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptorProceedings of the National Academy of Sciences of the United States of America, 2006
- Phenotypic evaluation of the basal-like subtype of invasive breast carcinomaLaboratory Investigation, 2005
- Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?Journal of Clinical Oncology, 2005
- Targeting death and decoy receptors of the tumour-necrosis factor superfamilyNature Reviews Cancer, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- Human breast cancer cell lines as models of growth regulation and disease progressionJournal of Mammary Gland Biology and Neoplasia, 1996
- MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGFBiochemical and Biophysical Research Communications, 1985